Published in Ann Oncol on February 13, 2008
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn (2010) 2.44
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol (2011) 2.06
Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol (2009) 1.80
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med (2010) 1.68
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs (2008) 1.21
More is less -- combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol (2009) 1.15
Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One (2009) 1.15
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer (2012) 1.13
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol (2009) 1.09
Biology and significance of circulating and disseminated tumour cells in colorectal cancer. Langenbecks Arch Surg (2012) 1.01
Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol (2009) 0.97
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res (2009) 0.97
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist (2011) 0.96
The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann Coloproctol (2013) 0.95
Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. Chemother Res Pract (2012) 0.87
Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol (2016) 0.85
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer (2011) 0.85
Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol (2016) 0.85
Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol (2010) 0.84
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. MAbs (2009) 0.83
A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers. J Gastrointest Oncol (2013) 0.83
Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. J Oncol (2009) 0.82
Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC Med (2014) 0.82
Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis. Oncol Lett (2013) 0.82
The role of cetuximab as first-line treatment of colorectal liver metastases. HPB (Oxford) (2012) 0.81
Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol (2012) 0.81
Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol (2016) 0.79
Recent advances and significance of intra-arterial infusion chemotherapy in non-resectable colorectal liver metastasis. J Gastrointest Oncol (2013) 0.79
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. Mol Clin Oncol (2014) 0.79
Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol (2014) 0.79
Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D (2011) 0.79
The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials. Int J Clin Exp Med (2015) 0.78
Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. Int J Clin Exp Med (2015) 0.78
Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know? Sultan Qaboos Univ Med J (2008) 0.78
The role of oncogenes in gastrointestinal cancer. Gastrointest Cancer Res (2010) 0.78
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. J Gastrointest Oncol (2016) 0.78
Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. Onco Targets Ther (2012) 0.78
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. BMC Cancer (2012) 0.78
Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4). Int J Colorectal Dis (2017) 0.77
XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer. Oncol Lett (2014) 0.77
Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer. Indian J Surg Oncol (2016) 0.77
Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer. Onco Targets Ther (2013) 0.77
Second- and third-line treatment options for unresectable metastatic colorectal cancer. Gastrointest Cancer Res (2008) 0.77
Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases. World J Surg Oncol (2015) 0.77
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience (2015) 0.76
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics (2009) 0.76
Evolving role of cetuximab in the treatment of colorectal cancer. Cancer Manag Res (2009) 0.76
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol (2011) 0.76
First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. Onco Targets Ther (2009) 0.75
Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clin Exp Metastasis (2012) 0.75
Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin. Urol Ann (2010) 0.75
Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature. Int J Clin Oncol (2010) 0.75
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum (1984) 20.51
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med (2012) 15.43
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis (1989) 6.52
HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS (1992) 3.91
The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum (1984) 3.20
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol (2009) 2.74
Is surveillance of the small bowel indicated for Lynch syndrome families? Gut (2007) 2.42
Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol (1984) 2.38
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer (2011) 2.16
HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum (1989) 2.14
Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. Ann Rheum Dis (1990) 2.07
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol (2009) 2.04
Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives. Arthritis Rheum (1990) 2.01
Thorium dioxide-related haemangiosarcoma of the liver. Neth J Med (2007) 1.99
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg (2013) 1.98
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol (2009) 1.87
Significance of positive tests for rheumatoid factor in the prognosis of rheumatoid arthritis. A follow-up study. Ann Rheum Dis (1970) 1.84
Phenobarbital and the shoulder-hand syndrome. Ann Rheum Dis (1966) 1.82
In situ localization of lymphocyte subsets in synovial membranes of patients with rheumatoid arthritis with monoclonal antibodies. J Rheumatol (1982) 1.78
Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol (1984) 1.75
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer (2009) 1.75
Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol (1985) 1.74
Helicobacter pylori: a true carcinogen? Eur J Gastroenterol Hepatol (1998) 1.72
Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis (1992) 1.68
The nature of fluorescence emission in the red fluorescent protein DsRed, revealed by single-molecule detection. Proc Natl Acad Sci U S A (2001) 1.59
Noncontraceptive hormones and rheumatoid arthritis in perimenopausal and postmenopausal women. JAMA (1986) 1.59
Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut (2003) 1.55
A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med (1999) 1.52
Do medical students copy the drug treatment choices of their teachers or do they think for themselves? Eur J Clin Pharmacol (2009) 1.50
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Immunoglobulin phagocytosis by granulocytes from sera and synovial fluids in various rheumatoid and nonrheumatoid diseases. Ann Rheum Dis (1975) 1.50
Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol (1992) 1.46
Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst (1995) 1.43
Majority of hMLH1 mutations responsible for hereditary nonpolyposis colorectal cancer cluster at the exonic region 15-16. Am J Hum Genet (1996) 1.43
Quantitative aspects of the latex-fixation and Whaaler-Rose tests. Ann Rheum Dis (1970) 1.43
Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol (2007) 1.42
Acute tumor lysis syndrome in a patient with multiple myeloma treated with dexamethasone monotherapy. Neth J Med (2001) 1.39
The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a family and population study. Br J Rheumatol (1983) 1.37
Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum (1991) 1.36
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
[Mucocutaneous manifestations of amyloidosis]. Ned Tijdschr Geneeskd (2007) 1.35
The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (1985) 1.34
Cervical myelopathy in rheumatoid arthritis. Clin Exp Rheumatol (1985) 1.33
Pregnancy and the risk of developing rheumatoid arthritis. Arthritis Rheum (1990) 1.33
Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol (2008) 1.31
Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol (2012) 1.31
BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol (1991) 1.30
Oral contraceptives and rheumatoid arthritis: further evidence for a preventive effect. Lancet (1982) 1.29
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer (2010) 1.26
A trial of consent procedures for future research with clinically derived biological samples. Br J Cancer (2009) 1.22
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs (2008) 1.21
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer (2003) 1.21
Rheumatoid factors in rheumatoid arthritis and vasculitis. Rheumatol Int (1985) 1.21
Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer (2010) 1.21
Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum (1988) 1.18
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol (2005) 1.17
Rheumatoid arthritis--the clinical significance of histo- and immunopathological abnormalities in normal skin. J Rheumatol (1984) 1.17
Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum Dis (1986) 1.15
Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus. Immunology (1980) 1.14
Immunogenetic heterogeneity of rheumatoid arthritis. Ann Rheum Dis (1986) 1.14
Frequency of infections among rheumatoid arthritis patients, before and after disease onset. Arthritis Rheum (1987) 1.13
Letter: HL-A 27 and ankylosing spondylitis. Lancet (1975) 1.13
Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. J Rheumatol (1990) 1.12
Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol (2011) 1.11
Gastrointestinal telangietasia as a cause of severe blood loss in systemic sclerosis. Endoscopy (1980) 1.10
Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut (1994) 1.09
Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg (2012) 1.08
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer (2008) 1.07
On standardization of the latex fixation test. Bull Rheum Dis (1976) 1.07
Non-gonococcal infectious arthritis: a retrospective study. J Infect (1987) 1.07
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol (2009) 1.07
Serum immune complexes containing IgA appear to predict erosive arthritis in a longitudinal study in rheumatoid arthritis. Ann Rheum Dis (1986) 1.06
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol (2006) 1.06
Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer (2010) 1.06
Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother (2008) 1.06
The value of tumour marker CA 125 in surgical pathology. Histopathology (1987) 1.04
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol (2014) 1.03
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer (2009) 1.03
Greater trochanteric pain syndrome (trochanteric bursitis) in low back pain. Scand J Rheumatol (1991) 1.03
Recombinant Salmonella vectors in vaccine development. Dev Biol Stand (1994) 1.03
Longterm cyclosporine therapy in rheumatoid arthritis. J Rheumatol (1991) 1.01
FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol (2006) 1.01